MA39337A1 - Modulateurs de pyrazines de gpr6 - Google Patents

Modulateurs de pyrazines de gpr6

Info

Publication number
MA39337A1
MA39337A1 MA39337A MA39337A MA39337A1 MA 39337 A1 MA39337 A1 MA 39337A1 MA 39337 A MA39337 A MA 39337A MA 39337 A MA39337 A MA 39337A MA 39337 A1 MA39337 A1 MA 39337A1
Authority
MA
Morocco
Prior art keywords
gpr6
modulators
pyrazines
compounds
methods
Prior art date
Application number
MA39337A
Other languages
English (en)
Other versions
MA39337B1 (fr
Inventor
Stephen Hitchcock
Holger Monenschein
Holly Reichard
Huikai Sun
Shota Kikuchi
Maria Hopkins
Mark E Adams
Jason W Brown
Betty Lam
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39337A1 publication Critical patent/MA39337A1/fr
Publication of MA39337B1 publication Critical patent/MA39337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (i) : qui sont utiles en tant que modulateurs de gpr6, des compositions pharmaceutiques de ceux-ci, des méthodes pour le traitement de conditions associées à gpr6, des procédés de fabrication de ces composés et des intermédiaires de ceux-ci.
MA39337A 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6 MA39337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940294P 2014-02-14 2014-02-14
PCT/US2015/015841 WO2015123533A1 (fr) 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6

Publications (2)

Publication Number Publication Date
MA39337A1 true MA39337A1 (fr) 2017-10-31
MA39337B1 MA39337B1 (fr) 2019-11-29

Family

ID=52598823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39337A MA39337B1 (fr) 2014-02-14 2015-02-13 Modulateurs de pyrazines de gpr6

Country Status (24)

Country Link
US (2) US10000468B2 (fr)
EP (1) EP3105216B1 (fr)
JP (1) JP6484640B2 (fr)
KR (1) KR20160122215A (fr)
CN (1) CN106103421B (fr)
AU (1) AU2015218402B2 (fr)
BR (1) BR112016018418A2 (fr)
CA (1) CA2939382A1 (fr)
CL (1) CL2016002043A1 (fr)
CR (1) CR20160428A (fr)
DO (1) DOP2016000211A (fr)
EA (1) EA033861B1 (fr)
EC (1) ECSP16074207A (fr)
ES (1) ES2702205T3 (fr)
GE (1) GEP20186893B (fr)
IL (1) IL247140B (fr)
MA (1) MA39337B1 (fr)
MX (1) MX369857B (fr)
MY (1) MY184366A (fr)
PE (1) PE20170245A1 (fr)
PH (1) PH12016501613A1 (fr)
UA (1) UA117779C2 (fr)
WO (1) WO2015123533A1 (fr)
ZA (1) ZA201606077B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160428A (es) * 2014-02-14 2017-04-04 Takeda Pharmaceuticals Co Pizazinas moduladoras de gpr6
CA3026784A1 (fr) 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Derives de pyrazine heterocycliques utiles en tant qu'inhibiteurs de shp2
EP3601239A4 (fr) 2017-03-23 2020-05-13 Jacobio Pharmaceuticals Co., Ltd. Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
DK3600312T3 (da) * 2017-03-26 2023-07-31 Takeda Pharmaceuticals Co Piperidinyl- og piperazinylsubstituerede heteroaromatiske carboxamider som modulatorer af gpr6
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
WO2001062765A2 (fr) * 1999-02-26 2001-08-30 Arena Pharmaceuticals, Inc. Modulateurs a petites molecules du recepteur six couple a la proteine g
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
DK1255740T3 (da) 2000-02-16 2006-02-06 Neurogen Corp Substituerede arylpyraziner
CN1245391C (zh) * 2001-06-01 2006-03-15 弗·哈夫曼-拉罗切有限公司 用作谷氨酸受体的嘧啶、三嗪和吡嗪衍生物
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
BR0307575A (pt) 2002-03-13 2004-12-21 Janssen Pharmaceutica Nv Derivados de sulfonila como inibidores de histona desacetilase
WO2004054617A1 (fr) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. Agents prophylactiques et/ou agents therapeutiques pour maladies du systeme nerveux central
PT1651620E (pt) 2003-07-30 2012-02-10 Xenon Pharmaceuticals Inc Derivados de piperizina e sua utilização como agentes terapêuticos
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CA2555402A1 (fr) 2004-02-12 2005-09-01 Celine Bonnefous Amides bipyridyles en tant que modulateurs du recepteur-5 metabotropique du glutamate
WO2005121126A1 (fr) 2004-04-13 2005-12-22 Icagen, Inc. Pyrazines polycycliques tenant lieu de modulateurs du canal ionique du potassium
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
EP1893212B1 (fr) 2005-05-13 2013-10-16 Lexicon Pharmaceuticals, Inc. Composes polycycliques et procedes pour les utiliser
WO2007044085A2 (fr) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
US8495335B2 (en) * 2006-06-16 2013-07-23 Raytheon Company Data translation system and method
JP2011524917A (ja) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用
ES2591004T3 (es) 2010-04-27 2016-11-24 Calcimedica, Inc. Compuestos moduladores del calcio intracelular
KR101564806B1 (ko) * 2010-05-13 2015-10-30 암젠 인크 Ｐｄｅ10 저해제로서 유용한 질소 헤테로시클릭 화합물
CA2798325A1 (fr) 2010-05-13 2011-11-17 Amgen Inc. Composes d'heteroaryloxyheterocyclyle convenant comme inhibiteurs de la pde10
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CA2853722A1 (fr) * 2011-10-27 2013-05-02 Mayo Foundation For Medical Education And Research Inhibition de polypeptides de recepteurs 6 kinases couples a une proteine g
US9487526B2 (en) * 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
WO2015061247A2 (fr) 2013-10-21 2015-04-30 Merck Patent Gmbh Composés hétéroaryle servant d'inhibiteurs de la btk et leurs utilisations
CR20160428A (es) * 2014-02-14 2017-04-04 Takeda Pharmaceuticals Co Pizazinas moduladoras de gpr6

Also Published As

Publication number Publication date
US10000468B2 (en) 2018-06-19
CN106103421A (zh) 2016-11-09
EA201691632A1 (ru) 2017-02-28
EA033861B1 (ru) 2019-12-03
JP2017509601A (ja) 2017-04-06
CL2016002043A1 (es) 2017-02-17
MA39337B1 (fr) 2019-11-29
GEP20186893B (en) 2018-09-10
WO2015123533A1 (fr) 2015-08-20
IL247140A0 (en) 2016-09-29
US20170174659A1 (en) 2017-06-22
PH12016501613B1 (en) 2017-02-06
IL247140B (en) 2020-02-27
EP3105216B1 (fr) 2018-10-10
JP6484640B2 (ja) 2019-03-13
CR20160428A (es) 2017-04-04
PE20170245A1 (es) 2017-03-30
MY184366A (en) 2021-04-01
KR20160122215A (ko) 2016-10-21
AU2015218402B2 (en) 2019-07-11
ES2702205T3 (es) 2019-02-27
MX369857B (es) 2019-11-25
CN106103421B (zh) 2019-04-09
MX2016010529A (es) 2016-10-31
BR112016018418A2 (pt) 2017-08-08
DOP2016000211A (es) 2016-10-16
US20180258073A1 (en) 2018-09-13
PH12016501613A1 (en) 2017-02-06
UA117779C2 (uk) 2018-09-25
EP3105216A1 (fr) 2016-12-21
US10273225B2 (en) 2019-04-30
ZA201606077B (en) 2018-11-28
ECSP16074207A (es) 2017-09-29
AU2015218402A1 (en) 2016-09-15
CA2939382A1 (fr) 2015-08-20

Similar Documents

Publication Publication Date Title
CO2017005218A2 (es) Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden los compuestos”
CO2017005452A2 (es) Compuestos que modulan la enzima oxidorreductasa indolamina 2,3-dioxigenasa (ido) y composiciones que comprenden tales compuestos
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
EA201790806A1 (ru) Иммунорегулирующие средства
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
BR112016028255A2 (pt) agentes imunorreguladores
EA201892123A1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
EA201691514A1 (ru) Соединения
MA40534A (fr) Inhibiteurs de mk2 et leurs utilisations
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
EA201790570A1 (ru) Модуляторы р2х7
MA40302B1 (fr) Dérivés de carbazole
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.